News & Insights

Oxford Technology & Innovations EIS Fund (OTIF) invests £350k in Series A funding in Cambridge cancer diagnostics company Biofidelity Ltd

  • Biofidelity Ltd is commercialising a novel molecular diagnostic technology that enables oncologists to target the most effective treatment to each individual patient and to monitor patients for response to treatments and recurrence of disease.
  • OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $12m Series A round led by BlueYard Capital, a Berlin-based venture capital firm.
  • This is the second OTIF investment in Biofidelity to date, bringing total funds invested by OTIF in the Company to £435k, in addition to investment in the technology through support of former parent company, Base4 Innovation Ltd.
Read post